Search Within

Population Sciences Research Program

  1. "Alison Moskowitz"
  2. "David Straus"
Formats
  1. Meeting Abstract (59)
  2. Journal Article (29)
Groups
  1. Center for Hematologic Malignancies (88)
  2. Department of Medicine (88)
  3. Hematologic Malignancies, Division of (88)
  4. Lymphoma (88)
  5. Survivorship Research (83)
  6. Executive Committee, Center for Hematologic Malignancies (51)

More Groups

People
  1. Alison Moskowitz (88)
  2. David Straus (88)
  3. Steven Horwitz (88)
  4. Andrew Zelenetz (83)
  5. Ariela Noy (81)
  6. Matthew Matasar (77)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (6)
  4. 2021 (14)
  5. 2020 (11)
  6. 2019 (15)

More Years

Publications
  1. Blood (43)
  2. Hematological Oncology (11)
  3. Journal of Clinical Oncology (8)
  4. Blood Advances (5)
  5. Blood Cancer Journal (5)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (48)
  2. Wiley Blackwell (11)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (5)
  5. American Association for Cancer Research (3)
  6. Elsevier Inc. (3)

More Publishers

Results (88)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save